<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826159</url>
  </required_header>
  <id_info>
    <org_study_id>IMB101-005</org_study_id>
    <nct_id>NCT04826159</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of IMB-1018972 on Cardiac Energetics in Patients With Type 2 Diabetes (IMPROVE-DiCE)</brief_title>
  <official_title>A Pharmacodynamic Study to Evaluate the Effects of IMB-1018972 on Myocardial Energetics, Metabolism, and Function in Patients With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imbria Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imbria Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic&#xD;
      reserve at rest and during stress and to assess safety and tolerability&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cardiac PCr/ATP ratio with dobutamine stress (ie, dobutamine stress-induced drop in PCr/ATP ratio from its resting value at the same time point) measured by 31P-MRS</measure>
    <time_frame>Baseline, End of Treatment (up to 8 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs</measure>
    <time_frame>Baseline through End of Treatment (up to 8 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Diabetic Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>IMB-1018972 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMB-1018972</intervention_name>
    <description>Modified release tablet for oral administration</description>
    <arm_group_label>IMB-1018972 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes&#xD;
&#xD;
          -  Elevated HbA1c&#xD;
&#xD;
          -  Elevated BMI&#xD;
&#xD;
          -  Preserved left ventricular ejection fraction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Contraindication to magnetic resonance scanning&#xD;
&#xD;
          -  More than mild to moderate valvular heart disease&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  History of sustained ventricular tachycardia or cardiac arrest&#xD;
&#xD;
          -  Clinically significant concurrent condition which could prevent the patient from&#xD;
             performing any of the protocol-specified assessments, represent a safety concern if&#xD;
             the patient participates in the trial or could confound trial assessments of safety or&#xD;
             tolerability&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Chamberlin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imbria Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Jauregui</last_name>
    <phone>6176754060</phone>
    <email>DiCE_ClinicalTrial@Imbria.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oxford University Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+44 (0)1865 2 2527987</phone>
      <email>DiCE_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Diabetic Cardiomyopathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

